Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multicentre, Open-label, Single Arm Study to Evaluate the Effectiveness and Safety of Rezafungin (as Acetate) in the Treatment of Chronic Pulmonary Aspergillosis (CPA) in Patients With Limited Treatment Options

NCT06794554 is registered in ClinicalTrials.gov with Mundipharma Research Limited as lead sponsor.

NCT NCT06794554
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06794554 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multicentre, Open-label, Single Arm Study to Evaluate the Effectiveness and Safety of Rezafungin (as Acetate) in the Treatment of Chronic Pulmonary Aspergillosis (CPA) in Patients With Limited Treatment Options
Lead sponsor
Mundipharma Research Limited
Phase
Phase 2
Overall status
Active, not recruiting
Start date
June 30, 2025
Completion date
December 30, 2026
Enrollment
60 (estimated)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

chronic pulmonary aspergillosis